Lefebvre V, Behringer R R, de Crombrugghe B
Department of Molecular Genetics, The University of Texas, MD Anderson Cancer Center, Houston 77030, USA.
Osteoarthritis Cartilage. 2001;9 Suppl A:S69-75. doi: 10.1053/joca.2001.0447.
This work was carried out to identify transcription factors controlling the differentiation of mesenchymal cells into chondrocytes.
We delineated a cartilage-specific enhancer in the collagen type 2 gene (Col2a1) and identified transcription factors responsible for the activity of this enhancer in chondrocytes. We then analyzed the ability of these transcription factors to activate specific genes of the chondrocyte differentiation program and control cartilage formation in vivo.
A 48-bp sequence in the first intron of Col2a1 drove gene expression specifically in cartilage in transgenic mouse embryos. The transcription factors L-Sox5, Sox6, and Sox9 bound and cooperatively activated this enhancer in vitro. They belong to the Sry-related family of HMG box DNA-binding proteins, which includes many members implicated in cell fate determination in various lineages. L-Sox5, Sox6, and Sox9 were coexpressed in all precartilaginous condensations in mouse embryos and continued to be expressed in chondrocytes until the cells underwent final hypertrophy. Whereas L-Sox5 and Sox6 are highly homologous proteins, they are totally different from Sox9 outside the HMG box domain. The three proteins cooperatively activated the Col2a1- and aggrecan genes in cultured cells. Heterozygous mutations in SOX9 in humans lead to campomelic dysplasia, a severe and generalized skeletal malformation syndrome. Embryonic cells with a homozygous Sox9 mutation were unable to form cartilage in vivo and activate essential chondrocyte marker genes. Preliminary data indicated that the mutation of Sox5 and Sox6 in the mouse led to severe skeletal malformations.
L-Sox5, Sox6, and Sox9 play essential roles in chondrocyte differentiation and, thereby, in cartilage formation. Their discovery will help to understand further the molecular mechanisms controlling chondrogenesis in vivo, uncover genetic mechanisms underlying cartilage diseases, and develop novel strategies for cartilage repair.
开展此项研究以鉴定控制间充质细胞分化为软骨细胞的转录因子。
我们在2型胶原基因(Col2a1)中描绘了一个软骨特异性增强子,并鉴定了负责该增强子在软骨细胞中活性的转录因子。然后我们分析了这些转录因子激活软骨细胞分化程序特定基因以及在体内控制软骨形成的能力。
Col2a1第一内含子中的一个48碱基对序列在转基因小鼠胚胎中驱动基因特异性地在软骨中表达。转录因子L-Sox5、Sox6和Sox9在体外结合并协同激活该增强子。它们属于HMG盒DNA结合蛋白的Sry相关家族,该家族包括许多与各种谱系细胞命运决定有关的成员。L-Sox5、Sox6和Sox9在小鼠胚胎的所有前软骨凝聚物中共同表达,并在软骨细胞中持续表达,直至细胞经历最终肥大。虽然L-Sox5和Sox6是高度同源的蛋白质,但它们在HMG盒结构域外与Sox9完全不同。这三种蛋白质在培养细胞中协同激活Col2a1和聚集蛋白聚糖基因。人类SOX9的杂合突变导致弯肢侏儒症,这是一种严重的全身性骨骼畸形综合征。具有纯合Sox9突变的胚胎细胞在体内无法形成软骨,也无法激活基本的软骨细胞标记基因。初步数据表明,小鼠中Sox5和Sox6的突变会导致严重的骨骼畸形。
L-Sox5、Sox6和Sox9在软骨细胞分化以及由此在软骨形成中起重要作用。它们的发现将有助于进一步了解体内控制软骨形成的分子机制,揭示软骨疾病的遗传机制,并开发软骨修复的新策略。